MedTrace Logo

Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

NCT00148551 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2007-07-30

No results posted yet for this study

Summary

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Triamcinolone Acetonide

Sponsors & Collaborators

  • University of British Columbia

    collaborator OTHER

  • QLT Inc.

    collaborator INDUSTRY

  • Vancouver Hospital

    collaborator UNKNOWN

  • Canadian Retinal Trials Group

    lead OTHER

Principal Investigators

  • David A Maberley, M.D. · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2008-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148551 on ClinicalTrials.gov